Ray Dalio Still Part of Danantara Team, Executives Say
Main Takeaways
|
JAKARTA, Investortrust.id — Top executives at Indonesia's sovereign wealth fund BPI Danantara have denied reports that American billionaire Ray Dalio has decided to withdraw from its advisory board, reaffirming his continued involvement in ongoing discussions.
Rosan Roeslani, Chief Executive Officer of BPI Danantara, and Pandu Patria Sjahrir, the fund’s Chief Investment Officer, made the statement following their attendance at a state ceremony welcoming French President Emmanuel Macron at the Presidential Palace in Jakarta on Wednesday, May 28, 2025.
Rosan said he met with Dalio’s team, including his son Mark Dalio, just last week. “Our discussions went smoothly,” Rosan told reporters. “I just met his team, and we also had a Zoom call recently. No, there's no such issue,” he said, referring to the speculation that Dalio had opted out.
The Indonesian government had announced Dalio’s appointment to Danantara’s advisory board in March alongside four other prominent global figures. The move was seen as a signal of international confidence in Indonesia's newly formed strategic investment arm, which aims to bolster national resilience through long-term, sustainable investments.
Rosan emphasized that Dalio remains part of the Danantara team. “We’re still in active discussions,” he said, adding that he had met the “whole team” recently.
Pandu echoed Rosan’s remarks and questioned the credibility of the reports suggesting Dalio had withdrawn. “We’re still in communication,” Pandu said. “Just last month we met with the CEO, and last week with his son.”
Reports of Dalio’s alleged withdrawal emerged from a Bloomberg article published Wednesday, citing anonymous sources who claimed the Bridgewater Associates founder had opted out for reasons that remain unclear. The report surfaced barely two months after the Indonesian government made Dalio’s appointment public.
Danantara has been making headlines for its aggressive push into strategic sectors. The fund recently announced plans to invest in healthcare and has projected potential annual dividend returns of up to Rp 163 trillion ($10.2 billion).